Elective node irradiation with integrated boost to the prostate using helical IMRT

• Verfasst von: Körber, Stefan A. [VerfasserIn]
• Verfasst von: Winter, Erik [VerfasserIn]
• Verfasst von: Katayama, Sonja [VerfasserIn]
• Verfasst von: Slynko, Alla [VerfasserIn]
• Verfasst von: Häfner, Matthias [VerfasserIn]
• Verfasst von: Uhl, Matthias [VerfasserIn]
• Verfasst von: Sterzing, Florian [VerfasserIn]
• Verfasst von: Habl, Gregor [VerfasserIn]
• Verfasst von: Schubert, Kai [VerfasserIn]
• Verfasst von: Debus, Jürgen [VerfasserIn]
• Verfasst von: Herfarth, Klaus [VerfasserIn]
• Titel: Elective node irradiation with integrated boost to the prostate using helical IMRT
• Titelzusatz: clinical outcome of the prospective PLATIN-1 trial
• Verf.angabe: Stefan Alexander Koerber, Erik Winter, Sonja Katayama, Alla Slynko, Matthias Felix Haefner, Matthias Uhl, Florian Sterzing, Gregor Habl, Kai Schubert, Juergen Debus and Klaus Herfarth
• E-Jahr: 2019
• Jahr: 13 August 2019
• Fussnoten: Gesehen am 09.10.2019
• Titel Quelle: Enthalten in: Frontiers in oncology
• Ort Quelle: Lausanne : Frontiers Media, 2011
• Jahr Quelle: 2019
• Band/Heft Quelle: 9(2019) Artikel-Nummer 751, 8 Seiten
• ISSN Quelle: 2234-943X
• DOI: doi:10.3389/fonc.2019.00751
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Elective node irradiation
• Sach-SW: IMRT (intensity modulated radiation therapy)
• Sach-SW: Pelvic nodes
• Sach-SW: prostate cancer
• Sach-SW: Radiotherapy
• Sach-SW: simultaneous integrated boost (SIB)
• Sach-SW: Tomotherapy ®
• K10plus-PPN: 1678623547
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

Introduction: This prospective, non-randomized phase II trial aimed to investigate the role of additional irradiation of the pelvic nodes for patients with prostate cancer and a high risk for nodal metastases using helical intensity-modulated radiotherapy with daily image guidance (IMRT/IGRT). Methods and materials: Between 2009 and 2012, 40 men with treatment-naïve prostate cancer and a risk of lymph node involvement of more than 20% were enrolled in the PLATIN-1 trial. All patients received definitive, helical IMRT of the pelvic nodes (total dose of 51.0 Gy) with a simultaneous integrated boost (SIB) to the prostate (total dose of 76.5 Gy) in 34 fractions. Antihormonal therapy (AHT) was administered for a minimum of two months before radiotherapy continuing for at least 24 months. Results: After a median follow-up of 71 months (range: 5 - 95 months), pelvic irradiation was associated with a 5-year overall survival (OS) and biochemical progression-free survival (bPFS) of 94.3% and 83.6%, respectively. For our cohort, no grade 4 gastrointestinal (GI) and genitourinary (GU) toxicity was observed. Quality of life (QoL) assessed by EORTC QLQ-C30 questionnaire was comparable to EORTC reference values without significant changes. Conclusion: The current trial demonstrates that elective IMRT/IGRT of the pelvic nodes with SIB to the prostate for patients with a high-risk of lymphatic spread is safe and shows an excellent clinical outcome without compromising the quality of life. The PLATIN-1 trial delivers eminent baseline data for future studies using modern irradiation techniques.